100 Participants Needed

taVNS for Dyslexia

TC
Overseen ByTracy Centanni, PhD
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: University of Florida
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does allow medications prescribed for ADHD.

How does the taVNS treatment for dyslexia differ from other treatments?

taVNS (transcutaneous auricular vagus nerve stimulation) is unique because it involves stimulating the vagus nerve through the skin of the ear, which is different from traditional dyslexia treatments that often focus on educational interventions. This approach is novel as it targets neurological pathways potentially involved in dyslexia, rather than relying solely on behavioral or educational strategies.12345

What is the purpose of this trial?

This is a pilot study to establish feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) for improving letter-learning in adolescents with dyslexia. The main goals of the study are to 1) evaluate whether children in this age range will tolerate low level stimulation over the course of multiple sessions, 2) determine whether low level taVNS improves novel letter learning in dyslexia, and 3) evaluate the effect of low level taVNS on the brain's response to letters. Participants will complete fMRI before training, immediately after training, and a few weeks after training ends. Training will consist of six 30-minute lessons during which participants will learn novel letter-sound relationships while receiving either active or sham taVNS. Researchers will compare stimulation conditions to determine effect of this device on learning and neural plasticity.

Eligibility Criteria

This trial is for adolescents with dyslexia who can read at a certain level (scores above or below 90 on reading measures) and have normal non-verbal IQ. It's not for those with other neurological conditions like autism or epilepsy, nor for those taking medications besides ADHD prescriptions.

Inclusion Criteria

You read very well, or you have trouble reading and may have ADHD.
You have a normal non-verbal IQ.

Exclusion Criteria

I am not on ADHD medication.
Your nonverbal IQ is lower than 80.
You have a neurological condition like autism or epilepsy.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive six 30-minute lessons to learn novel letter-sound relationships while receiving either active or sham taVNS

4 weeks
6 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including fMRI assessments

6 weeks
2 visits (in-person)

Treatment Details

Interventions

  • active taVNS
  • sham taVNS
Trial Overview The study tests if taVNS, a low-level nerve stimulation given during letter-learning sessions, helps improve reading skills in dyslexic teens. Participants will receive either real taVNS or sham (fake) treatment to see which is more effective.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active taVNSExperimental Treatment1 Intervention
Participants will receive custom current at 5 Hz to the left auricular branch of the vagus nerve while learning new letter-sound relationships.
Group II: Sham taVNSPlacebo Group1 Intervention
Participants will undergo current thresholding but device will be turned off without their knowledge during the training.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials
1,428
Recruited
987,000+

Findings from Research

Brivaracetam (BRV) shows a significantly higher affinity for the synaptic vesicle protein SV2A compared to levetiracetam, which correlates with its strong antiepileptic activity in animal models.
BRV inhibits voltage-dependent sodium currents in rat neocortical neurons in a concentration-dependent manner, suggesting that this modulation of sodium inflow may contribute to its effectiveness as an antiepileptic drug.
Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.Zona, C., Pieri, M., Carunchio, I., et al.[2016]

References

Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. [2016]
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. [2021]
Healthy and diseased corticospinal motor neurons are selectively transduced upon direct AAV2-2 injection into the motor cortex. [2018]
SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. [2021]
Adeno-Associated Viral Vectors in Neuroscience Research. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security